Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 5:57 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 169–192 of 611 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Iron Clear all
Completed Phase 3 Interventional Results available

VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

NCT00317239
View directory record Official record
Conditions
Anemia
Interventions
Ferrous Sulfate tablets, Ferric Carboxymaltose (FCM)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
12 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Norristown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease

NCT01052779
View directory record Official record
Conditions
Iron Deficiency, Anemia, Kidney Disease
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
14
States / cities
Tempe, Arizona • Chula Vista, California • Mountain View, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD Patients

NCT01894906
View directory record Official record
Conditions
Kidney Failure
Interventions
Soluble Ferric Pyrophosphate, Placebo
Drug · Other
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 19, 2026, 5:57 PM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Iron Deficiency Anemia (IDA) and the Brain

NCT05929729
View directory record Official record
Conditions
IDA - Iron Deficiency Anemia, Anemia, Iron Deficiency Anemia, Anemia, Iron Deficiency
Interventions
Ferric derisomaltose, NovaFerrum
Drug
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
16 Years to 60 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab and Magnetic Resonance Imaging With Ferumoxytol in Treating Patients With Non-small Cell Lung Cancer and Brain Metastases

NCT03325166
View directory record Official record
Conditions
Lung Carcinoma Metastatic in the Brain, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ferumoxytol, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Pembrolizumab
Drug · Other · Procedure + 1 more
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 19, 2026, 5:57 PM EDT
Approved For Marketing No phase listed Expanded access

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease

NCT00293098
View directory record Official record
Conditions
Iron Overload
Interventions
deferiprone
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 9, 2012 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Colorado-Oregon Altitude Study

NCT05734716
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Erythropoietin, Iron sucrose (Venofer), Sterile Sodium Chloride
Drug
Lead sponsor
University of Oregon
Other
Eligibility
18 Years to 40 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
2
States / cities
Leadville, Colorado • Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

NCT01671111
View directory record Official record
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
SSP-004184AQ
Drug
Lead sponsor
Shire
Industry
Eligibility
6 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Oakland, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Not applicable Interventional

Iron Depletion Therapy for Type 2 DM and NAFLD

NCT00230087
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Diabetes Mellitus
Interventions
blood donation
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Phase 1 Interventional

Study of Safety and Tolerability of VLX600, an Iron Chelator, in Patients With Refractory Advanced Solid Tumors

NCT02222363
View directory record Official record
Conditions
Refractory Cancer
Interventions
VLX600
Drug
Lead sponsor
Vivolux AB
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 19, 2026, 5:57 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Iron Deficiency and FGF23 Regulation in CKD and HF

NCT03106298
View directory record Official record
Conditions
Chronic Kidney Diseases, Chronic Heart Failure, Iron Deficiency Anemia
Interventions
Iron Sucrose
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 20, 2019 · Synced Oct 19, 2026, 5:57 PM EDT
Not yet recruiting Phase 4 Interventional

IV Iron Therapy for Older Adults With Heart Failure With Preserved Ejection Fraction and Iron Deficiency

NCT07686692
View directory record Official record
Conditions
Heart Failure With Preserved Ejection Fraction, Iron Deficiency
Interventions
Ferric derisomaltose, Placebo (normal saline)
Drug
Lead sponsor
Duke University
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Iron Aid IPS on Performance, Fatigue and Iron Levels During 12 Weeks of Supplementation and Aerobic Training

NCT03523455
View directory record Official record
Conditions
Iron-deficiency
Interventions
Iron Aid IPS (Iron Protein Succinylate), Sugar Pill
Dietary Supplement · Other
Lead sponsor
University of Mary Hardin-Baylor
Other
Eligibility
18 Years to 30 Years · Female only
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Belton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

NCT03802916
View directory record Official record
Conditions
Iron Overload Due to Repeated Red Blood Cell Transfusions
Interventions
Deferiprone DR tablets 1000 mg (Low dosage), Deferiprone DR tablets 1000 mg (High dosage)
Drug
Lead sponsor
ApoPharma
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
2
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2021 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Study of Iron Isomaltoside 1000 Administered by 250 mg IV Bolus Injection or 500 mg Intravenous Infusion to Patients With Non-hematological Malignancies Associated With Chemotherapy Induced Anaemia

NCT01280240
View directory record Official record
Conditions
Patients With Chemotherapy Induced Anemia (CIA)
Interventions
Monofer(R)
Drug
Lead sponsor
Pharmacosmos A/S
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
2
States / cities
Baltimore, MD, Maryland • Canton, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 4 Interventional Results available

Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis

NCT01227616
View directory record Official record
Conditions
Iron Deficiency Anemia Treatment, Chronic Kidney Disease(CKD)
Interventions
Ferumoxytol, Iron Sucrose
Drug
Lead sponsor
AMAG Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
38
States / cities
Pine Bluff, Arkansas • Azusa, California • Beverly Hills, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

NCT02189889
View directory record Official record
Conditions
Anemia, Cardiovascular Disease
Interventions
EPO, Feraheme
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 19, 2026, 5:57 PM EDT
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Iron Overload After Undergoing a Donor Stem Cell Transplant

NCT00602446
View directory record Official record
Conditions
Breast Cancer, Iron Overload, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer
Interventions
deferasirox
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cystatin SN Binds to Phytic Acid and Predicts Non-heme Iron Bioavailability

NCT03030703
View directory record Official record
Conditions
Iron-deficiency, Iron Deficiency Anemia
Interventions
phytic acid
Dietary Supplement
Lead sponsor
Kansas State University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Manhattan, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2017 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Iron and the Breast-Fed Infant: Iron Status and Two Regimens of Iron Supplementation

NCT00760890
View directory record Official record
Conditions
Iron Deficiency
Interventions
Fer-In-Sol (ferrous sulfate), Iron fortified cereal
Dietary Supplement
Lead sponsor
National Institutes of Health (NIH)
NIH
Eligibility
1 Month to 24 Months
Enrollment
171 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2005
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Sep 26, 2008 · Synced Oct 19, 2026, 5:57 PM EDT
Not listed Phase 3 Interventional

Ferumoxytol-enhanced Magnetic Resonance Imaging

NCT02954510
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ferumoxytol
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic Hemodialysis

NCT00548249
View directory record Official record
Conditions
End-Stage Renal Disease (ESRD)
Interventions
Standard Bicarbonate Solution, Soluble Ferric Pyrophosphate
Device · Drug
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Tempe, Arizona • Hacienda Heights, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Oct 19, 2026, 5:57 PM EDT
Completed Not applicable Interventional Results available

Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases

NCT00103038
View directory record Official record
Conditions
Central Nervous System Lymphoma, Malignant Glioma, Metastatic Malignant Neoplasm in the Brain
Interventions
3 Tesla Magnetic Resonance Imaging, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol, Gadolinium, MRI-Based Angiogram
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 19, 2026, 5:57 PM EDT
Suspended Phase 2 Interventional

Evaluation of Novel Iron-based Lymphatic Mapping Agent, Magtrace, for Delayed Sentinel Lymph Node Biopsy (SLNB) in Ductal Carcinoma In-Situ (DCIS)

NCT06868238
View directory record Official record
Conditions
Ductal Carcinoma in Situ
Interventions
Magtrace
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 19, 2026, 5:57 PM EDT